Houston Center for Infectious Diseases provides the following vaccines to prevent the Meningococcal disease:
Meningococcal conjugate vaccines (protects against serogroups A, C, W, and Y) MENACTRA®
Meningococcal polysaccharide vaccine: quadrivalent (protects against serogroups A, C, W, and Y) meningococcal vaccine MENOMUNE
Serogroup B meningococcal vaccine (MenB): monovalent (protects against serogroup B) meningococcal vaccine TRUMEMBRA
There are meningococcal vaccines that help provide protection against five types (serogroups) of meningococcal disease, including the three types most common in the United States (serogroups B, C, and Y). Meningococcal vaccines cannot prevent all cases of the disease, but they do protect many people who might become sick if they didn't get vaccinated.
Either meningococcal conjugate vaccine (MENACTRA®) or meningococcal polysaccharide vaccine (MENOMUNE) is recommended for adults if you:
Have a damaged spleen or your spleen has been removed
Have complement component deficiency
Are a microbiologist who is routinely exposed to Neisseria meningitidis (the causal pathogen)
Are traveling to or residing in countries in which the disease is common
Are part of a population identified to be at increased risk because of a serogroup A, C, W, or Y meningococcal disease outbreak
Are a college freshman living in a dormitory
Are a military recruit
Booster doses may be recommended for adults who remain at increased risk. Talk to your health care provider for more information.
284 Menactra® (Meningococcal Groups A, C, Y and W-135)
Highlights of Prescribing Information
These highlights do not include all the information needed to use Menactra® safely and effectively.
Menactra® Meningococcal (Groups A, C, Y and W-135) Polysacharide
Diphtheria Toxoid Conjugated Vaccine
Solution for Intramuscular injection
Initial U.S. Approval: 2005
Indications and Usage
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups, A, C, Y and W-135. Menanctra vaccine is approved for use in individuals 9 months through 55 years old. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Dosage and Administration
A 0.5 ml dose for intramuscular injection
Children 9 through 23 moths of age: two doses, three months apart
Individuals 2 through 55 years of age: A single dose
A single booster dose may be given to individuals 15 through 55 years of age at continuous risk of meningococcal disease, if at least 4 years have elapsed since the prior dose.
Dosage Form and Strengths
Solution supplied in 0.5ml single-dose vials
Severe allergic reaction (e.g. anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide, diphtheria toxoid or CRM197 containing vaccine, or to any other component of Menactra vaccine.
TRUMENBA® (Meningococcal Group B Vaccine)
Until recently, there were no serogroup B meningococcal vaccines licensed for use in the United States.
Serogroup B meningococcal vaccination is recommended for people 10 years and older at increased risk for meningococcal disease, including people identified to be at increased risk because of a serogroup B meningococcal disease outbreak. Clinicians can use serogroup B meningococcal vaccines for people 10 through 25 years old consistent with the labeled indication.
TRUMENBA (Meningococcal Group B Vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidisserogroup B in individuals aged 10 through 25 years of age.
Meningococcal vaccines are now available that help protect against all three serogroups of meningococcal disease that are most commonly seen in the United States (serogroups B, C and Y), but they will not prevent all cases. There are three kinds of meningococcal vaccines available in the United States:
Meningococcal conjugate vaccines (Menactra®, MenHibrix® and Menveo®)
Meningococcal polysaccharide vaccine (Menomune®)
Serogroup B meningococcal vaccines (Bexsero® and Trumenba®)
TRUMENBA was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs.